Trial Profile
An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants <5 kg Body Weight
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Mar 2019
Price :
$35
*
At a glance
- Drugs Artemether/lumefantrine (Primary)
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 30 Apr 2015 New trial record
- 19 Dec 2012 Status change from not yet recruiting to recruiting, as per ClinicalTrials.gov record.